S&P Futures
4,070.25 -14.00 (-0.34%) Dow Futures
33,947.00 -99.00 (-0.29%) Nasdaq Futures
12,172.25 -50.00 (-0.41%) Russell 2000 Futures
1,912.10 -7.40 (-0.39%) Crude Oil
79.15 -0.53 (-0.67%) Gold
1,946.10 +0.50 (+0.03%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 111.07 |
| Open | 110.65 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 109.81 - 111.26 |
| 52 Week Range | 93.25 - 130.94 |
| Volume | |
| Avg. Volume | 4,894,713 |
| Market Cap | 191.706B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 28.12 |
| EPS (TTM) | 3.91 |
| Earnings Date | Apr 18, 2023 - Apr 24, 2023 |
| Forward Dividend & Yield | 2.04 (1.86%) |
| Ex-Dividend Date | Jan 12, 2023 |
| 1y Target Est | 122.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ABT
Related Research
- Abbott LaboratoriesThe Argus Min Vol Model PortfolioRapidly rising inflation 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower last year. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those fixed-income returns are from eras when the 10-year Treasury bond yield was much higher than the current 3.5% level. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate.RatingFair ValueEconomic Moat4 days agoArgus Research
- Motley Fool
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
- Simply Wall St.
Abbott Laboratories Full Year 2022 Earnings: EPS Beats Expectations
Abbott Laboratories ( NYSE:ABT ) Full Year 2022 Results Key Financial Results Revenue: US$43.7b (up 1.3% from FY 2021...
- Insider Monkey
Abbott Laboratories (NYSE:ABT) Q4 2022 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q4 2022 Earnings Call Transcript January 25, 2023 Operator: Good morning and thank you for standing by. Welcome to Abbott’s Fourth Quarter 2022 Earnings Conference Call. This call is being recorded by Abbott. With the exception of any participants’ questions asked during the question-and-answer session, the entire call, including the question-and-answer session, […]
